Introduction
Dravet syndrome is a severe epileptic encephalopathy, most frequently caused by a mutation in the SCN1A gene. It is characterized by onset of recurrent febrile and/or afebrile hemiclonic or generalized seizures in a previously healthy infant in the first 15 months of their life. This is usually followed by appearance of multiple seizure types, generally resistant to antiepileptic drugs, with developmental arrest or regression [8, 7] . Epileptic seizures often encountered are atypical absences, tonic seizures, myoclonic seizures and tonic clonic seizures. The tonic clonic seizures with a focal onset persist into adulthood but with increasing age there is a reduction in the number of atypical absences and myoclonic seizures. In addition to the seizures and cognitive impairment, a progressive loss of mobility is seen partly due to cerebellar impairment [15] . Prognosis is bleak with a mortality rate, also in the adult group, between 15 and 20% [10] . Most of these deaths are related to complications of a status epilepticus or due to 'sudden unexpected death in epilepsy (SUDEP)'.
There is evidence for the efficacy of stiripentol (STP), based on two randomized controlled trials. In these add-on trials STP was added to a treatment regime with valproate and clobazepam (STICLO France, Lancet 2000, STICLO Italy (not published)). Levetiracetam, topiramate and zonisamide appear to be helpful, but clinical evidence is weak (or randomized trials are not available). In addition, there are 'medication to avoid' especially concerning lamotrigine, phenytoin and carbamazepine. For lamotrigine this was carefully documented by Guerrini et al. [11] . They found an increase of tonic clonic and myoclonic seizures in 17 of the 21 patients with Dravet syndrome who were on lamotrigine. However, for the advice to avoid phenytoin and carbamazepine, there is less scientific evidence.
The theoretical background for a potential increase in seizure frequency by sodium channel blockers is based on the expression pattern of the SCN1A mutation [5] . The SCN1A gene codes for the SCN1 alpha protein, a subunit of the voltage gated sodium channel. Voltage gated channels are the basis for every action potential, explaining their relation with epilepsy. Dravet syndrome is usually caused by 'loss of function' mutations and for this a loss of excitation would be expected. However, SCN1A mice models show a loss of excitation of the GABA-ergic interneurons without a relevant effect of the SCN1A mutation on the excitatory pyramidal neurons [19] . So, in the mouse model the epilepsy is explained by a loss of inhibition of the GABA-ergic interneurons. The use of sodium channels blockers will, in this model, further reduce the already impaired inhibition. Benzodiazepines and stiripentol are assumed to be effective because of their GABA-ergic effect. Drugs like levetiracetam, topiramate, valproate en zonisamide have an indirect effect on GABA-ergic neurons that might explain their efficacy.
A negative effect of carbamazepine was reported in the large series of Brunklaus et al. [3] , where carbamazepine was the drug that was most often associated with a paradoxical effect.
Supported by these data we decided to withdraw carbamazepine in one of our adult patients with Dravet syndrome, who was on polytherapy and had frequent myoclonic seizures. The effect of carbamazepine withdrawal was a reduction in myoclonic seizures but an increase of tonic seizures. These tonic seizures evolved into a status epilepticus which was complicated by a bilateral pneumonia, due to which the patient ultimately died. Based on this experience we decided to investigate the effect of medication alteration, in particular the withdrawal of carbamazepine (CBZ) and oxcarbazepine (OXC) on seizure type and seizure frequency in adult patients with Dravet syndrome.
Material and methods
The digital medical records of all our adult patients living in Kempenhaeghe (a tertiary care facility for people with epilepsy and an intellectual disability) with a genetically confirmed diagnosis of Dravet syndrome, were reviewed. Diagnostic criteria for Dravet syndrome as proposed by Dravet et al. [8] were used in addition to the SCN1A mutation. Out-patients were excluded, as were patients with an epileptic encephalopathy not related to Dravet syndrome.
We identified 16 adult patients. Information concerning gender, age, age at onset, type of SCN1A mutation, severity of intellectual disability, and mortality were documented.
In addition, the treatment, duration of treatment with CBZ/OXC and the effect of a change in these medications on seizure type and seizure frequency were noted. Digital medical and pharmacy records, including a graphical rendering of seizure type and frequency, were available since 1992.
All available clinical and investigational information was reviewed.
Seizure types in adulthood where all classified by the neurologist in the past. In many cases video-EEG did not cover all seizure types.
Seizure frequency and type of seizures as it was documented over the years by the nursing staff was carefully studied but the conclusion whether there was a change in seizure type and frequency after the start or withdrawal of CBZ/OXC was ultimately based on the documented (written) clinical judgement of the consultant neurologist at the time of the anti-epileptic drug adjustment.
To identify if the seizure frequency was ''increased'' or ''decreased'', we used a time-frame of 3 months of clinical data after the last dosage reduction or complete stop. Possible related clinical factors, when documented were collected in the database.
Results
The study population consisted of 10 men and 6 women. Demographic and clinical data are summarized in Table 1 . Median age was 35 years (range 20-61 years).
Carbamazepine (CBZ)
A total of eleven patients in the study-population (68.75%) used CBZ during their lifetime.
Details are presented in Table 2 .
In nine of these patients, an attempt to withdraw CBZ was made at some stage. In six patients CBZ was completely stopped. The reason to withdraw the medication varied from 'no efficacy', 'side effects' to 'based on the current literature'. In three of the nine patients (33%), an increase in tonic clonic seizures was noted.
In three patients (case 1.4 and 9) the CBZ was replaced by either Lamictal (case 1) or Stiripentol (case 4 and 9), in the six other patients the CBZ was not replaced by another anti-epileptic drug after reduction or withdrawal. In patient number 4 a possible precipitating factor of seizure aggravation was a recent fever period caused by a respiratory tract infection. In the other patients no possible related clinical factor during the reduction/withdrawal period was documented in the medical records.
Oxcarbazepine (OXC)
A total of five patients in the study-population (31.25%) used OXC during their lifetime.
Details are presented in Table 3 .
In three patients an attempt to withdraw was made, in two patients a complete stop was possible.
In one patient the myoclonic seizures reduced after the complete stop, in the other patient there was no change in seizure control.
In one patient (case 5) the OXC was replaced by CBZ, in the other 2 patients (case 14 and 16) the OXC was not replaced by another anti-epileptic drug after reduction or withdrawal.
In patient number 14 a possible precipitating factor of seizure aggravation was a recurrent respiratory tract infection and feeding problems.
In the other patients no possible related clinical factor during the reduction/withdrawal period was documented in the medical records.
Mortality
Four patients died in total. Three of the four deaths were related to epilepsy.
In two patients the status epilepticus, either convulsive or myoclonic, was complicated by a bilateral pneumonia. Both patients had a previous status epilepticus during their lifetime.
In one of these two patients the final status epilepticus developed during the reduction of OXC. The third patient died of SUDEP two years after the last reduction of CBZ.
Discussion and conclusion
The withdrawal of carbamazepine in our institutionalized adult Dravet patients induced an increase of tonic clonic seizures in three out of nine subjects. In one patient the withdrawal of carbamazepine was, in time, related to an increase of convulsive seizures that attributed to her death. Although our experience is based on a small population the study is, in a way, unbiased as we included all our institutionalized adult SCN1A positive Dravet patients. Still, due to the retrospective nature of the study, the results should be interpreted with care.
Our retrospective data appears to be in contrast with the available, also retrospectively acquired, data from the literature. In 2011, Dravet and Guerrini [9] referred to three publications that suggest a deterioration of seizure control after the start of carbamazepine. In one of these publications [16] (N = 6) there was a deterioration of seizure control in four patients and no effect in two subjects. In the second publication [12] (N = 9) carbamazepine induced an increase of seizure frequency in two, side effects in five, and a positive effect in two patients. The third publication [17] (N = 10) showed a similar result. In addition to these studies, there are two relatively recent large 'clinical' Dravet studies [3, 18] looking at the effect of medication. In the manuscript by Brunklaus et al. [3] (N = 241), there were sixty patients who showed a deterioration after the start of medication. In thirty-six of these sixty patients (60%) the deterioration was caused by carbamazepine. However, it was not described how often a positive or equivocal effect was seen. In the study by Xu (N = 138), forty patients were treated with carbamazepine of whom sixteen (40%) showed an increase in seizure frequency. There was no effect of carbamazepine in the other twenty-four patients.
There are various possible explanations for the differences in outcome between these studies and our results. First, in the previous studies, the effect of carbamazepine was studied in patients in whom carbamazepine was started, not in patients where it was discontinued. Secondly, in the literature the focus is on children whereas in our study we only included adult patients. This might be relevant as the chance of secondary lesions inducing a change in seizure type that is responsive to carbamazepine is higher in the adult group. This hypothesis is supported by the high percentage of patients with tonic seizures that was encountered in our adult patients, a type of seizure that is only rarely observed in children with Dravet syndrome or in previously studied adult patient groups. However, as was pointed out by several authors: ''Some of the major convulsive seizures in adult DS have less typical aspects, for example, bilateral or asymmetric tonic posturing followed in some cases by a tonic vibratory state or clonic movements'' [1, 10, 14] . For this, it is possible that the convulsive seizures that in our institute were classified as tonic, could in some cases also have been classified as 'atypical tonic clonic'. We also have to take into account that, in addition, a difference in age could be accompanied by a change in the expression of the SCN1A gene.
The expression of sodium channels is age-dependent, which explains the age of seizure onset after an initially normal development [5] . In Dravet syndrome, seizure patterns change with age. In adult patients convulsive and dyscognitive seizures may become prominent. Serial interictal or ictal EEGs tend to show evidence a focal onset, while myoclonic seizures, atypical absences and photosensitivity eventually diminish or disappear in adulthood [1, 4, 10] . Furthermore, in mouse models, the antiepileptic efficacy of stiripentol diminishes with age [2] and combinations of drugs may be synergistic for one seizure type, but not for another [13] .
Important for the current concept of seizures in patients with Dravet syndrome is the selective expression of sodium channels. There are various subtypes with a different regional expression pattern that is dependent on maturation [5] . It is well possible that age, chronic polytherapy or secondary neuronal damage change the expression pattern of ion channels in specific brain regions that might disrupt the balance between inhibition and excitation that will have consequences for the appropriate treatment regime.
Even in the studies that pointed out the risk of carbamazepine on seizure frequency in patients with Dravet syndrome, there were some patients in whom the carbamazepine could not be discontinued. This was well recognized by Dravet who observed that: ''In some older patient taking polytherapies, including carbamazepine, lamotrigine and phenytoin, attempt of drug withdrawal were followed by aggravation of epilepsy'' [9] .
The percentage of 25% patients who died in our study appears relatively high as compared to the percentage of 15-20% that is mentioned in the literature [10] . This percentage might be explained by the small number of patients, the fact that in one patient the cause of death was not related to epilepsy and the severity of clinical features of our institutionalized patients. The study is too small to compare the mortality risk in those patients who have been on carbamazepine and those who have not.
We conclude that, based on the available literature, there is a relative contraindication for the use of sodium channel blockers in newly diagnosed patients with Dravet syndrome. The information concerning patients 3, 9 and 16 shows that in adult patients, the reduction of (ox)carba(ma)zepine could lead to a (partially) better seizure control. However, our data also indicate that the evidence to withdraw carbamazepine (or oxcarbazepine) is still inadequate and the withdrawal of these drugs should be very closely monitored by a neurologist that is aware of both the benefits and risks. We suggest that (ox)carba(ma)zepine withdrawal should be considered in these patients but only if there is a good reason to do so and only if they are closely monitored.
